Biomarker analysis in the CheckMate 238 study revealed that higher levels of IFN-γ gene expression profiling, tumor PD-L1 expression, a higher CD8+ T cell infiltrate in tumors and tumor mutational burden (TMB) were associated with favorable RFS and OS with both nivolumab and ipilimumab as an adjuvant treatment [40]. The gene discussed is IFNG; the disease is neoplasm.